Tomorrow is "Announcement allocation of late-breaking abstracts to authors" at EHA.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Transcript of today KPTI presentation at RBC.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
New paper, Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Selinexor is in more than 30 presentations at EHA2025.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Today they mentioned again that they have profitable MM business
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Last year, Karyopharm reported 1stQ24 earnings on May 8. They haven't announced it yet this year. Are they waiting for something to happen?
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
New paper, Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Interesting review paper "Modulation of anti-tumour immunity by XPO1 inhibitors"
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Titles for ASCO 2025 presentations including Selinexor.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Trump’s FDA Sends a Bullish Signal to Biotech
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Reading modifications of EC-042 trial in recently issued 10-K.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
MiniReview just published, "Targeting the undruggable MYC in cancer: the rationale of using XPO1 inhibitors"
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
AACR2025 presentation, Exportin 1 as a novel therapeutic target in gastroenteropancreatic neuroendocrine tumors.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Interesting read on attempts to target p53 in cancer
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
The results of "A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma" are published.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Interesting paper, "XPO1-dependency of DEK::NUP214 leukemia"
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Antengene reported annual results.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Karyopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Selinexor data at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer, to be held on March 14-17 in Seattle, Washington.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Selinexor at Fourth Annual National General Medical Oncology Summit, Friday-Sunday, February 28 – March 2, 2025, Miami, Florida
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
On Thursday, H.C. Wainwright reaffirmed its Buy rating and $7.00 price target for Karyopharm Therapeutics (NASDAQ:KPTI) shares.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
New paper, Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis.
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
Are we going to have an update on communication with FDA regarding EC and MM trials in coming earning call?
KPTI - Killer Profits, Taking Incentives Investment Club - Not Financial Advice Not related to Karyopharm in Any Way
